Safety and Efficacy of Fidaxomicin Versus Placebo for Prophylaxis Against Clostridium Difficile-Associated Diarrhea in Adults Undergoing Hematopoietic Stem Cell Transplantation (MK-5119-001)

NCT01691248 · clinicaltrials.gov ↗
PHASE3
Phase
COMPLETED
Status
611
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

Optimer Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)